Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PanBlok H5N1 Vaccine Phase 2 Trial
NCT01612000Phase 2Completed
- Sponsor
- Protein Sciences
- Start
- May 2012
- Primary completion
- Aug 2013
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Panblok in Influenza A H5N1 infection (H5N1) (4 arms), sponsored by Protein Sciences. Primary endpoints: Difference in Seroconversion/Immunogenicity at 42 days and Difference in Geometric Mean Titer at 42 days. Started May 2012; status: completed.
02
Drugs
Panblok
03
Conditions
Influenza A H5N1 infection (H5N1)
Beyond the preview
Go deeper on NCT01612000.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01612000.